Ameriprise Financial Inc. raised its stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 15.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 531,354 shares of the company's stock after acquiring an additional 69,550 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.18% of Stevanato Group worth $11,578,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in STVN. M&T Bank Corp acquired a new stake in shares of Stevanato Group during the fourth quarter worth $572,000. Mutual of America Capital Management LLC purchased a new position in Stevanato Group during the fourth quarter worth approximately $13,848,000. Advantage Alpha Capital Partners LP raised its position in Stevanato Group by 27.3% during the fourth quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company's stock worth $6,403,000 after acquiring an additional 63,041 shares during the period. Allianz SE purchased a new position in Stevanato Group in the 4th quarter valued at about $748,000. Finally, Zions Bancorporation N.A. lifted its holdings in Stevanato Group by 29.7% in the 4th quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock valued at $1,482,000 after purchasing an additional 15,555 shares in the last quarter.
Stevanato Group Stock Performance
STVN stock traded down €0.37 ($0.42) during midday trading on Friday, reaching €22.24 ($25.27). The company had a trading volume of 159,500 shares, compared to its average volume of 343,538. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.82) and a fifty-two week high of €25.75 ($29.26). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The stock has a 50 day moving average price of €21.72 and a 200 day moving average price of €21.33. The firm has a market capitalization of $6.74 billion, a PE ratio of 47.32, a P/E/G ratio of 7.18 and a beta of 0.51.
Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.23). The company had revenue of €352.68 million for the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.
Stevanato Group Increases Dividend
The business also recently announced an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be issued a $0.0613 dividend. This is a positive change from Stevanato Group's previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. Stevanato Group's payout ratio is 11.76%.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on STVN shares. UBS Group lowered their price objective on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. William Blair reiterated an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Finally, Stephens raised shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Stevanato Group currently has a consensus rating of "Moderate Buy" and an average target price of €25.70 ($29.20).
Check Out Our Latest Research Report on Stevanato Group
Stevanato Group Profile
(
Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Articles
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
